<DOC>
	<DOC>NCT00855647</DOC>
	<brief_summary>To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.</brief_summary>
	<brief_title>Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Eligible patients will have clinical stage T1c through T2b, initial PSA level &lt;10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved. Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed. Adult men will be considered. No life expectancy restrictions will apply. Performance Status will not be considered. No requirements for organ or marrow function will be made Ability to understand and the willingness to sign a written informed consent document. No prior prostate treatment will be allowed. The use of other concurrent Investigational Agents will not be allowed. No exclusion requirements due to comorbid disease or incurrent illness. No requirements regarding history of allergic reactions. Pregnancy or nursing patients is not applicable (ie. patients are male).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>